Drug Profile
Influenza A virus vaccine H1N1 - GC Biopharma
Alternative Names: GC 1116Latest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Green Cross
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus H1N1 subtype
Most Recent Events
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 01 Jan 2014 Discontinued - Phase-III for Influenza-A virus H1N1 subtype in South Korea (IM)
- 01 Oct 2009 Phase-III clinical trials in Influenza-A virus H1N1 subtype (prevention in adults and elderly) in South Korea (IM)